What is Ebglyss approved to treat?
Ebglyss (lebrikizumab-lbkz) is indicated for adults with moderate-to-severe atopic dermatitis (eczema) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. It can be used with or without topical corticosteroids.[1]
How does Ebglyss work for eczema?
Ebglyss is an interleukin-13 (IL-13) inhibitor that targets a key protein driving inflammation in atopic dermatitis. It's administered as a subcutaneous injection, typically starting with two doses two weeks apart, then every two weeks.[1]
Who qualifies for Ebglyss treatment?
Patients must have moderate-to-severe atopic dermatitis confirmed by a clinician, with inadequate response to at least one topical medication like corticosteroids or calcineurin inhibitors. It's not for mild cases or as first-line therapy.[1]
When was Ebglyss FDA approved?
The FDA approved Ebglyss in September 2024 for the atopic dermatitis indication, following positive phase 3 trial data showing significant skin clearance.[1]
What are common side effects patients report?
Herpes infections (like cold sores), injection site reactions, and conjunctivitis occur in more than 1% of users. Serious eye problems or hypersensitivity reactions are possible but rare.[1]
How does Ebglyss compare to Dupixent?
Both are injectables for moderate-to-severe atopic dermatitis, but Ebglyss specifically blocks IL-13, while Dupixent (dupilumab) blocks both IL-4 and IL-13. Ebglyss may offer dosing convenience (every two weeks after loading) and showed comparable efficacy in trials.[1]
Sources:
[1]: FDA Prescribing Information for Ebglyss